Changes

Newer edit →

Diabetic foot ulcer

58,966 bytes added, 14:53, 17 February 2010

no edit summary

Diabetic foot ulcer is one of the major complications of Diabetes mellitus. It occurs in 15% of all patients with diabetes and precedes 84% of all lower leg amputations.[1]. Major increase in mortality among diabetic patients, observed over the past 20 years is considered to be due to the development of macro and micro vascular complications, including failure of the wound healing process. Wound healing is a ‘make-up’ phenomenon for the portion of tissue that gets destroyed in any open or closed injury to the skin. Being a natural phenomenon, wound healing is usually taken care of by the body’s innate mechanism of action that works reliably most of the time. Key feature of wound healing is stepwise repair of lost extracellular matrix (ECM) that forms largest component of dermal skin layer.[2] Therefore controlled and accurate rebuilding becomes essential to avoid under or over healing that may lead to various abnormalities. But in some cases, certain disorders or physiological insult disturbs wound healing process that otherwise goes very smoothly in an orderly manner. Diabetes mellitus is one such metabolic disorder that impedes normal steps of wound healing process. Many histopathological studies show prolonged inflammatory phase in diabetic wounds, which causes delay in the formation of mature granulation tissue and a parallel reduction in wound tensile strength.[3]
Non-healing chronic diabetic ulcers are often treated with extracellular matrix replacement therapy. So far, it is a common trend in diabetic foot care domain to use advanced moist wound therapy, bio-engineered tissue or skin substitute, growth factors and negative pressure wound therapy.[4] No therapy is completely perfect as each type suffers from its own disadvantages. Moist wound therapy is known to promote fibroblast and keratinocyte proliferation and migration, collagen synthesis, early angiogenesis and wound contraction. At present, there are various categories of moist dressings available such as adhesive backing film, silicone coated foam, hydrogels, hydrocolloids etc. Unfortunately, all moist dressings cause fluid retention; most of them require secondary dressing and hence are not the best choice for exudative wounds.[5] To address the physiological deficiencies underlying diabetic ulcer, various tissue engineering technologies have come up with cellular as well as acellular skin replacement products.
<table id="toc" class="toc">
<tbody>
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
[hide]</div>
<ul>
<li class="toclevel-1 tocsection-1">1 Prevention </li>
<li class="toclevel-1 tocsection-2">2 Risk factors </li>
<li class="toclevel-1 tocsection-3">3 Pathophysiology
<ul>
<li class="toclevel-2 tocsection-4">3.1 Role of Extracellular matrix (ECM) in wound healing </li>
<li class="toclevel-2 tocsection-5">3.2 Altered metabolism </li>
</ul>
</li>
<li class="toclevel-1 tocsection-6">4 Treatment </li>
<li class="toclevel-1 tocsection-7">5 Future directions </li>
<li class="toclevel-1 tocsection-8">6 References </li>
<li class="toclevel-1 tocsection-9">7 See also </li>
<li class="toclevel-1 tocsection-10">8 External links </li>
</ul>
</td>
</tr>
</tbody>
</table>
<script type="text/javascript">
//<![CDATA[
if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); }
//]]>
</script>
<h2>Prevention</h2>
Prevention is by frequent chiropody review, good foot hygiene, diabetic socks and shoes, and avoiding injury.
<ul>
<li>Foot-care education combined with increased surveillance can reduce the incidence of serious foot lesions [6]. </li>
</ul>
<ul>
<li>Footwear. </li>
</ul>
<dl><dd>All major reviews recommend special footwear for patients with a prior ulcer or with foot deformities. One review added neuropathy as an indication for special footwear. The comparison of custom shoes versus well-chosen and well-fitted athletic shoes is not clear. </dd></dl><dl><dd>A meta-analysis by the Cochrane Collaboration concluded that "there is very limited evidence of the effectiveness of therapeutic shoes" [7]. The date of the literature search for this review is not clear. Clinical Evidence reviewed the topic and concluded "Individuals with significant foot deformities should be considered for referral and assessment for customised shoes that can accommodate the altered foot anatomy. In the absence of significant deformities, high quality well fitting non-prescription footwear seems to be a reasonable option" [8]. National Institute for Health and Clinical Excellence has reviewed the topic and concluded that for patients at "high risk of foot ulcers (neuropathy or absent pulses plus deformity or skin changes or previous ulcer" that "specialist footwear and insoles" should be provided [9] </dd></dl>
The one randomized controlled trial that showed benefit of custom foot wear was in patients with a prior foot ulceration [10]. In this trial, the number needed to treat was 4 patients.
<h2>Risk factors</h2>
Two main risk factors that cause diabetic foot ulcer are Diabetic neuropathy and micro as well as macro ischemia.[11] Diabetic patients often suffer from diabetic neuropathy due to several metabolic and neurovascular factors. Type of neuropathy called peripheral neuropathy causes loss of pain or feeling in the toes, feet, legs and arms due to distal nerve damage and low blood flow. Blisters and sores appear on numb areas of the feet and legs such as metatarso-phalangeal joints, heel region and as a result pressure or injury goes unnoticed and eventually become portal of entry for bacteria and infection.
<h2>Pathophysiology</h2>
<h3>Role of Extracellular matrix (ECM) in wound healing</h3>
Extra cellular matrix is the structurally stable material that lies under epidermal layer and surrounds connective tissue cells that form dermal layer of the skin. Through the interaction of cell with its extracellular matrix, there forms a continuous association between cell interior, cell membrane and extracellular matrix components that help drive various cellular events in a regulated fashion.[12] Wound healing, a repair mechanism is one of those cellular events that occur through controlled turnover of extracellular matrix components. Because of this extracellular matrix is often considered as a 'conductor of the wound healing symphony'.[13] In the Inflammatory phase, neutrophils and macrophages recruit and activate fibroblasts which in subsequent granulation phase migrate into the wound, laying down new collagen of the subtypes I and III. In the initial events of wound healing, collagen III predominates in the granulation tissue which later on in remodeling phase gets replaced by collagen I giving additional tensile strength to the healing tissue.[14][15] It is evident from the known collagen assembly that the tensile strength is basically due to fibrillar arrangement of collagen molecules, which self assemble into microfibrils in a longitudinal as well as lateral manner producing extra strength and stability to the collagen assembly.[15][16] Metabolically altered collagen is known to be highly inflexible and prone to breakdown, particularly over pressure areas. Fibronectin is the major glycoprotein secreted by fibroblasts during initial synthesis of extracellular matrix proteins. It serves important functions, being a chemo-attractant for macrophages, fibroblasts and endothelial cells. Basement membrane that separates epidermis from the dermal layer and endothelial basement membrane mainly contain collagen IV that forms a sheet like pattern and binds to other extra cellular matrix molecules like laminin and proteoglycans. In addition to collagen IV, epidermal and endothelial basement membrane also contain laminin, perlecan and nidogen.[15][16] Hyaluronic acid, a pure glycosaminoglycan component is found in high amounts in damaged or growing tissues. It stimulates cytokine production by macrophages and thus promotes angiogenesis. In normal skin chondroitin sulfate proteoglycan is mainly found in the basement membrane but in healing wounds they are up regulated throughout the granulation tissue especially during second week of wound repair, when they provide a temporary matrix with highly hydrative capacity.[17] Binding of growth factors is clearly an important role of perlecan in wound healing and angiogenesis. Poor wound healing in diabetes mellitus may be related to perlecan expression. High levels of glucose can decrease perlecan expression in some cells probably through transcriptional and post-transcriptional modification.[17][18] Wound healing phases especially, granulation, re-epithelization and remodeling exhibit controlled turnover of extracellular matrix components.
<h3>Altered metabolism</h3>
Diabetes mellitus is a metabolic disorder and hence the defects observed in diabetic wound healing are thought to be the result of altered protein and lipid metabolism and thereby abnormal granulation tissue formation.[19] Increased glucose levels in the body end up in uncontrolled covalent bonding of aldose sugars to a protein or lipid without any normal glycosylation enzymes.[20] These stable products then accumulate over the surface of cell membranes, structural proteins and circulating proteins. These products are called advanced glycation endproducts (AGEs) or Amadori products. Formation of AGEs occurs on extracellular matrix proteins with slow turnover rate. AGEs alter the properties of matrix proteins such as collagen, vitronectin, and laminin through AGE-AGE intermolecular covalent bonds or cross-linking.[20][21][22] AGE cross-linking on type I collagen and elastin results in increased stiffness. AGEs are also known to increase synthesis of type III collagen that forms the granulation tissue. AGEs on laminin result in reduced binding to type IV collagen in the basement membrane, reduced polymer elongation and reduced binding of heparan sulfate proteoglycan.[20]
<dl><dt>Impaired NO synthesis </dt></dl>
Nitric oxide is known as an important stimulator of cell proliferation, maturation and differentiation. Thus, nitric oxide increases fibroblast proliferation and thereby collagen production in wound healing. Also, L-arginine and nitric oxide are required for proper cross linking of collagen fibers, via proline, to minimize scarring and maximize the tensile strength of healed tissue.[23] Endothelial cell specific nitric oxide synthase (EcNOS) is activated by the pulsatile flow of blood through vessels. Nitric oxide produced by EcNOS, maintains the diameter of blood vessels and proper blood flow to tissues. In addition to this, nitric oxide also regulates angiogenesis, which plays a major role in wound healing.[24] Thus, diabetic patients exhibit reduced ability to generate nitric oxide from L-arginine. Reasons that have been postulated in the literature include accumulation of nitric oxide synthase inhibitor due to high glucose associated kidney dysfunction and reduced production of nitric oxide synthase due to ketoacidosis observed in diabetic patients and pH dependent nature of nitric oxide synthase.[20][25]
<dl><dt>Structural and functional changes in fibroblasts </dt></dl>
Diabetic ulcer fibroblasts show various morphological differences compared to fibroblasts from age matched controls. Diabetic ulcer fibroblasts are usually large and widely spread in the culture flask compared to the spindle shaped morphology of the fibroblasts in age-matched controls. They often show dilated endoplasmic reticulum, numerous vesicular bodies and lack of microtubular structure in transmission electron microscopy study. Therefore, interpretation of these observations would be that in spite of high protein production and protein turnover in diabetic ulcer fibroblasts, vesicles containing secretory proteins could not travel along the microtubules to release the products outside.[26][27] Fibroblasts from diabetic ulcer exhibit proliferative impairment that probably contributes to a decreased production of extracellular matrix proteins and delayed wound contraction and impaired wound healing.[26]
<dl><dt>Increased matrix metalloproteinases (MMP) activity </dt></dl>
In order for a wound to heal, extracellular matrix not only needs to be laid down but also must be able to undergo degradation and remodeling to form a mature tissue with appropriate tensile strength.[28] Proteases, namely matrix metalloproteinases are known to degrade almost all the extracellular matrix components. They are known to be involved in fibroblast and keratinocyte migration, tissue re-organization, inflammation and remodeling of the wounded tissue.[3][28] Due to persistently high concentrations of pro-inflammatory cytokines in diabetic ulcers, MMP activity is known to increase by 30 fold when compared to acute wound healing.[29] MMP-2 and MMP-9 show sustained overexpression in chronic non-healing diabetic ulcers.[3][30] Balance in the MMP activity is usually achieved by tissue inhibitor of metalloproteinases (TIMP). Rather than absolute concentrations of either two, it is the ratio of MMP and TIMP that maintains the proteolytic balance and this ratio is found to be disturbed in diabetic ulcer.[31][32] In spite of these findings, the exact mechanism responsible for increased MMP activity in diabetes is not known yet. One possible line of thought considers Transforming growth factor beta (TGF-β) as an active player. Most MMP genes have TGF-β inhibitory element in their promoter regions and thus TGF–β regulates the expression of both MMP and their inhibitor TIMP.[33] In addition to the importance of cell-cell and cell-matrix interactions, all phases of wound healing are controlled by a wide variety of different growth factors and cytokines. To mention precisely, growth factors promote switching of early inflammatory phase to the granulation tissue formation. Decrease in growth factors responsible for tissue repair such as TGF-β is documented in diabetic wounds. Thus, reduced levels of TGFβ in diabetes cases lower down the effect of inhibitory regulatory effect on MMP genes and thus cause MMPs to over express.[1][34][35]
<h2>Treatment</h2>
Foot ulcers in diabetes require multidisciplinary assessment, usually by diabetes specialists and surgeons. Treatment consists of appropriate bandages, antibiotics (against staphylococcus, streptococcus and anaerobe strains), debridement and arterial revascularisation.
It is often 500 mg to 1000 mg of flucloxacillin, 1 g of amoxicillin and also metronidazole to tackle the putrid smelling bacteria.
Specialists are investigating the role of nitric oxide in diabetic wound healing.[36] Nitric oxide is a powerful vasodilator, which helps to bring nutrients to the oxygen deficient wound beds. Specialists are using forms of light therapy, such as LLLT (Low level laser therapy) to treat diabetic ulcers.
In 2004, The Cochrane review panel concluded that for people with diabetic foot ulcers, hyperbaric oxygen therapy reduced the risk of amputation and may improve the healing[37] at 1 year.[38] They also suggest that the availability of hyperbaric facilities and economic evaluations should be interpreted.[38]
<dl><dt>Cellular wound matrices </dt></dl>
These type of matrices are used as dermal or both dermal-epidermal substitutes. They are made up of In vitro cultured fibroblasts or keratinocytes onto a biomaterial mesh. As cells proliferate across the mesh, they secrete human dermal collagen, matrix proteins, growth factors and cytokines to create three-dimensional human dermal substitute containing metabolically active living cells. Thus by restoring the dermal tissue, they cause patient’s own epithelial cells to migrate and close the wound.[4][39] Unlike dermal substitutes, dermal-epidermal substitutes have a combined dermal and epidermal layer. The epidermal layer is composed of live, differentiating keratinocytes, while the dermal layer consists of living fibroblasts.[40]
<dl><dt>Acellular wound matrices </dt></dl>
Along the same line, some diabetic wounds may be treated by application of natural or synthetic acellular wound matrices that act as a scaffold at the tissue site to promote fibroblast and keratinocyte migration, to assist in wound closure and thus provide an optimal environment for a restoration of tissue structure and function. These matrices come in different forms. 1. sterile peel open packages for one time use only: In this form, matrix is formulated in the form of a sheet, which has to be cut in a size larger than the outline of wound area either in a dry state or in rehydrated state.[41] 2. Flowable Soft tissue Scaffold: Sometimes, even after surface portion of wound has healed, a remaining tunnel that left treated can lead to breakdown of the wound and formation of new ulcer with easy access to bacteria to cause potentially deep infection.[42] Therefore, this matrix form is made to be applied with a syringe into tunnels or extensions in case of deep wounds. 3. Bilayer matrix wound dressing: This is a tissue engineered porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan and a semi permeable polysiloxane (silicone) layer. Semi permeable silicone membrane controls water vapor loss, provides a flexible adherent covering for the wound surface and adds tear strength to the device. Moreover, the collagen-glycosaminoglycan biodegradable matrix provides a scaffold for cellular invasion and capillary growth. Wound closure is typically complete within 30 days.[43]
<dl><dt>Negative pressure wound therapy </dt></dl>
<div class="rellink relarticle mainarticle">Main article: Negative pressure wound therapy</div>
This treatment uses vacuum to remove excess fluid and cellular waste that usually prolong the inflammatory phase of wound healing. In spite of very straightforward mechanism of action, there are lots of inconsistent results of negative pressure wound therapy studies. Research needs to be carried out to optimize the parameters of pressure intensity, treatment intervals and exact timing to start negative pressure therapy in the course of chronic wound healing.[44]
<dl><dt>Application of growth factors </dt></dl>
This treatment strategy consists of use of growth factors either as one of the components in matrix therapy or via topical application of formulation containing required growth factors. Research shows that growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) accelerate tissue repair in an experimental wound model. They attach to cell receptors regulating gene expression of several cytokines and chemokines via different signaling pathways. They promote cell division, migration, angiogenesis and thus start tissue regeneration and remodeling process.[34][45]
<h2>Future directions</h2>
Though, diabetic foot ulcer develops secondary to Diabetes mellitus, it is usually considered as a separate entity in the medicinal realm from the treatment perspective. With frequent and common incidences of Diabetes mellitus all over the world, diabetic foot care study is becoming a priority especially in the field of podiatry. Though, treatment approaches such as topical formulations of growth factors, cellular and acellular matrix applications show very promising results, these formulations are expensive and are generally either dermal or epidermal analogs; mostly being dermal analogs. Use of human cadaver and other animal skin sometimes faces the problem of tissue rejection or failure of revascularization. Among all other causes of delayed wound healing, except the metabolic cause i.e. excess glycation cannot be treated with either topical formulation or matrix application at wound site. Therefore, pharmaceutical companies should focus their research on development of drugs that can inhibit AGE formation and their potential formulations for diabetic patients. Topical or systemic administration of EcNOS can be one more potential treatment that needs to be considered in diabetic ulcers as well. Thus, while treating diabetic ulcers, generalized treatment approach does not seem to be appropriate instead, selection of a particular treatment should be carried out on case-by-case evaluation considering severity of the wound and by using combination therapy if necessary.[13]
<h2>References</h2>
<div class="references-small">
<ol class="references">
<li id="cite_note-Harold-0">^ a b Harold Brem, Marjana Tomic-Canic.Cellular and Molecular basis of wound healing in diabetes.JCI (2007),117(5):1219–1222. PMID 17476353. </li>
<li id="cite_note-Iakovos-1">^ Iakovos N Nomikos et al, Protective and Damaging Aspects of Healing: A Review, Wounds(2006). 18 (7): 177-185.[1] </li>
<li id="cite_note-McLennan-2">^ a b c McLennan S et al, Molecular aspects of wound healing, Primary intention(2006).14(1):8-13 [2] </li>
<li id="cite_note-Blume-3">^ a b Peter Blume et.al, Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial, Diabetes care(2008). 31: 631-636 PMID 18162494. </li>
<li id="cite_note-Sharman-4">^ Debbie Sharman, Moist wound healing: a review of evidence, application and outcome, The Diabetic Foot(2003). 6(3): 112-120 </li>
<li id="cite_note-pmid8498761-5">^ Litzelman D, Slemenda C, Langefeld C, Hays L, Welch M, Bild D, Ford E, Vinicor F (1993). "Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial". Ann Intern Med 119 (1): 36–41. PMID 8498761.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+of+lower+extremity+clinical+abnormalities+in+patients+with+non-insulin-dependent+diabetes+mellitus.+A+randomized%2C+controlled+trial&rft.jtitle=Ann+Intern+Med&rft.aulast=Litzelman+D%2C+Slemenda+C%2C+Langefeld+C%2C+Hays+L%2C+Welch+M%2C+Bild+D%2C+Ford+E%2C+Vinicor+F&rft.au=Litzelman+D%2C+Slemenda+C%2C+Langefeld+C%2C+Hays+L%2C+Welch+M%2C+Bild+D%2C+Ford+E%2C+Vinicor+F&rft.date=1993&rft.volume=119&rft.issue=1&rft.pages=36%E2%80%9341&rft_id=info:pmid/8498761&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-pmid10908550-6">^ Spencer S; Spencer, Sue A (2000). "Pressure relieving interventions for preventing and treating diabetic foot ulcers". Cochrane Database Syst Rev (3): CD002302. doi:10.1002/14651858.CD002302. PMID 10908550.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pressure+relieving+interventions+for+preventing+and+treating+diabetic+foot+ulcers&rft.jtitle=Cochrane+Database+Syst+Rev&rft.aulast=Spencer+S&rft.au=Spencer+S&rft.au=Spencer%2C%26%2332%3BSue+A&rft.date=2000&rft.issue=3&rft.pages=CD002302&rft_id=info:doi/10.1002%2F14651858.CD002302&rft_id=info:pmid/10908550&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-pmid16620415-7">^ Hunt D (2005). "Foot ulcers and amputations in diabetes". Clin Evid (14): 455–62. PMID 16620415. http://clinicalevidence.com/ceweb/conditions/dia/0602/0602_I5.jsp.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Foot+ulcers+and+amputations+in+diabetes&rft.jtitle=Clin+Evid&rft.aulast=Hunt+D&rft.au=Hunt+D&rft.date=2005&rft.issue=14&rft.pages=455%E2%80%9362&rft_id=info:pmid/16620415&rft_id=http%3A%2F%2Fclinicalevidence.com%2Fceweb%2Fconditions%2Fdia%2F0602%2F0602_I5.jsp&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-webNICE-8">^ "Scope: Management of type 2 diabetes: prevention and management of foot problems (update)" (PDF). Clinical Guidelines and Evidence Review for Type 2 Diabetes: Prevention and Management of Foot Problems. National Institute for Health and Clinical Excellence. 20 February 2003. http://www.nice.org.uk/nicemedia/pdf/footcare_scope.pdf. Retrieved 2007-12-04.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=bookitem&rft.btitle=Scope%3A+Management+of+type+2+diabetes%3A+prevention+and+management+of+foot+problems+%28update%29&rft.atitle=Clinical+Guidelines+and+Evidence+Review+for+Type+2+Diabetes%3A+Prevention+and+Management+of+Foot+Problems&rft.date=20+February+2003&rft.pub=National+Institute+for+Health+and+Clinical+Excellence&rft_id=http%3A%2F%2Fwww.nice.org.uk%2Fnicemedia%2Fpdf%2Ffootcare_scope.pdf&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-pmid8721941-9">^ Uccioli L, Faglia E, Monticone G, Favales F, Durola L, Aldeghi A, Quarantiello A, Calia P, Menzinger G (1995). "Manufactured shoes in the prevention of diabetic foot ulcers". Diabetes Care 18 (10): 1376–8. doi:10.2337/diacare.18.10.1376. PMID 8721941.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Manufactured+shoes+in+the+prevention+of+diabetic+foot+ulcers&rft.jtitle=Diabetes+Care&rft.aulast=Uccioli+L%2C+Faglia+E%2C+Monticone+G%2C+Favales+F%2C+Durola+L%2C+Aldeghi+A%2C+Quarantiello+A%2C+Calia+P%2C+Menzinger+G&rft.au=Uccioli+L%2C+Faglia+E%2C+Monticone+G%2C+Favales+F%2C+Durola+L%2C+Aldeghi+A%2C+Quarantiello+A%2C+Calia+P%2C+Menzinger+G&rft.date=1995&rft.volume=18&rft.issue=10&rft.pages=1376%E2%80%938&rft_id=info:doi/10.2337%2Fdiacare.18.10.1376&rft_id=info:pmid/8721941&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-Wu-10">^ Stephanie C Wu et al, Foot ulcers in the diabetic patient, prevention and treatment, Vasc Health Risk Manag, (2007).3(1):65-76 PMID 17583176. </li>
<li id="cite_note-11">^ Hay Elizabeth (1991). Cell biology of extracellular matrix second edition. New York: Plenum press. pp. 1–5. ISBN 0-306-40785-X.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=book&rft.btitle=Cell+biology+of+extracellular+matrix+second+edition&rft.aulast=Hay+Elizabeth&rft.au=Hay+Elizabeth&rft.date=1991&rft.pages=pp.%26nbsp%3B1%E2%80%935&rft.place=New+York&rft.pub=Plenum+press&rft.isbn=0-306-40785-X&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-Sweitzer-12">^ a b Sarah M. Sweitzer et al, What is the future of Diabetic wound care?, The Diabetes Educator(2006), 32(2):197-210 PMID 16554422. </li>
<li id="cite_note-Schultz-13">^ Schultz GS, Ludwig G, Wysocki A. Extracellular matrix: review of its roles in acute and chronic wounds. World Wide Wounds 2005. http://www.worldwidewounds.com/2005/august/Schultz/Extrace-Matric-Acute-Chronic-Wounds.html </li>
<li id="cite_note-Sussman-14">^ a b c Carrie Sussman (2006). Wound Care:a collaborative practice manual third Edition. Lippincott Williams & Wilkins. pp. 21–47. ISBN 9780781774444.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=book&rft.btitle=Wound+Care%3Aa+collaborative+practice+manual+third+Edition&rft.aulast=Carrie+Sussman&rft.au=Carrie+Sussman&rft.date=2006&rft.pages=pp.%26nbsp%3B21%E2%80%9347&rft.pub=Lippincott+Williams+%26+Wilkins&rft.isbn=9780781774444&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-Thomas-15">^ a b D.W.Thomas et al, Cutaneous wound healing: A current perspective, J Oral Maxil Surg (1995).53: 442-447 PMID 7699500. </li>
<li id="cite_note-Miriam-16">^ a b Miriam A.M. et al, Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds, J Invest Dermatol(1998). 111(5):850-857 PMID 9804349. </li>
<li id="cite_note-Decarlo-17">^ Decarlo, Arthur A et al, ‘Wound and cutaneous injury healing with a nucleic acid encoding perlecan’, United States Patent 7141551, Nov.2006 </li>
<li id="cite_note-Tweedie-18">^ Janet Close-Tweedie , Daibetic foot wounds and wound healing: a review, The Diabetic Foot(2002):68 </li>
<li id="cite_note-Goldin-19">^ a b c d Alison Goldin et al, Advanced glycation end products: Sparking the Development of Diabetic Vascular Injury, Circulation(2006). 114:597-605 PMID 16894049. </li>
<li id="cite_note-Singh-20">^ Singh R et al, Advanced glycation end-products: a review. Diabetologia(2001).44: 129–146 </li>
<li id="cite_note-Brownlee-21">^ Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med.(1995). 46: 223–234 PMID 7598459. </li>
<li id="cite_note-Kei-22">^ Kei Obayashi et al, Exogenous nitric oxide enhances the synthesis of type I collagen and heat shock protein 47 by normal human dermal fibroblasts, J Dermato Sci(2006). 41(2): 121-126 PMID 16171977. </li>
<li id="cite_note-Dan-23">^ Dan G. Duda et al, Role of eNOS in neovascularization: NO for endothelial progenitor cells, Trends Mol Med(2004).10(4): 143-145 PMID 15162796. </li>
<li id="cite_note-Linden-24">^ E. Linden et al, Endothelial Dysfunction in Patients with Chronic Kidney Disease Results from Advanced Glycation End Products (AGE)-Mediated Inhibition of Endothelial Nitric Oxide Synthase through RAGE Activation,Clin. J. Am. Soc. Nephrol(2008).3(3): 691 - 698 PMID 18256374. </li>
<li id="cite_note-fibroblasts-25">^ a b Miriam A.M. et al, Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non insulin dependent diabetes mellitus) show disturbed proliferation, Arch Dermatol Res(1999). 291: 93-99 PMID 10195396. </li>
<li id="cite_note-Rowe-26">^ Rowe DW et al, Abnormalities in proliferation and protein synthesis in skin fibroblast cultures from patients with diabetes mellitus, Diabetes(1997). 26: 284-290 PMID 849809. </li>
<li id="cite_note-Ravanti-27">^ a b Laura Ravanti et al, Matrix metalloproteases in wound repair (review), Int J Mol Med(2000). 6(4): 391-407 PMID 10998429 </li>
<li id="cite_note-Vaalamo-28">^ Vaalamo M et al, Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing, Hum Patho(1999). 30:795-802 PMID 10414498. </li>
<li id="cite_note-Wysocki-29">^ Wysocki AB et al, Wound fluid from chronic leg ulcers contains elevated levels of MMP-2 and MMP-9, J Invest Dermatol(1993). 101:64-68 PMID 8392530. </li>
<li id="cite_note-Lobman-30">^ R.Lobman et.al, Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non diabetic patients, Diabetologia(2002). 45:1011–1016 DOI 10.1007/s00125-002-0868-8 </li>
<li id="cite_note-Muller-31">^ M Muller et.al, Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing, Diabet Med(2008).25(4): 419-426 PMID 18387077. </li>
<li id="cite_note-Susan-32">^ Susan V Mclennan, Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy, Kidney Int(2000).58: S81-S87 PMID 10997695. </li>
<li id="cite_note-Bennet-33">^ a b Neil Bennett et al, Growth factors and wound healing: Part II. Role in normal and chronic wound healing, Am J Surg(1993). 166: 74-81 PMID 8392302. </li>
<li id="cite_note-Galkowska-34">^ Galkowska H et.al, Chemokines, cytokines and growth factors in keratinocytes and dermal endothelial cells in the margin if chronic diabetic foot ulcers, Wound Repair Regen(2006). 14:558-565 PMID 17014667. </li>
<li id="cite_note-35">^ Schäffer M, Bongartz M, Fischer S, Proksch B, Viebahn R (July 2007). "Nitric oxide restores impaired healing in normoglycaemic diabetic rats". J Wound Care 16 (7): 311–6. PMID 17708383.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nitric+oxide+restores+impaired+healing+in+normoglycaemic+diabetic+rats&rft.jtitle=J+Wound+Care&rft.aulast=Sch%C3%A4ffer+M%2C+Bongartz+M%2C+Fischer+S%2C+Proksch+B%2C+Viebahn+R&rft.au=Sch%C3%A4ffer+M%2C+Bongartz+M%2C+Fischer+S%2C+Proksch+B%2C+Viebahn+R&rft.date=July+2007&rft.volume=16&rft.issue=7&rft.pages=311%E2%80%936&rft_id=info:pmid/17708383&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-36">^ Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA (September 1997). "Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study". Undersea Hyperb Med 24 (3): 175–9. PMID 9308140. http://archive.rubicon-foundation.org/2279. Retrieved 2008-05-16.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+hyperbaric+oxygen+for+diabetic+wounds%3A+a+prospective+study&rft.jtitle=Undersea+Hyperb+Med&rft.aulast=Zamboni+WA%2C+Wong+HP%2C+Stephenson+LL%2C+Pfeifer+MA&rft.au=Zamboni+WA%2C+Wong+HP%2C+Stephenson+LL%2C+Pfeifer+MA&rft.date=September+1997&rft.volume=24&rft.issue=3&rft.pages=175%E2%80%939&rft_id=info:pmid/9308140&rft_id=http%3A%2F%2Farchive.rubicon-foundation.org%2F2279&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-CochraneHBO-37">^ a b Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S (2004). "Hyperbaric oxygen therapy for chronic wounds". Cochrane Database Syst Rev (2): CD004123. doi:10.1002/14651858.CD004123.pub2. PMID 15106239.<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hyperbaric+oxygen+therapy+for+chronic+wounds&rft.jtitle=Cochrane+Database+Syst+Rev&rft.aulast=Kranke+P%2C+Bennett+M%2C+Roeckl-Wiedmann+I%2C+Debus+S&rft.au=Kranke+P%2C+Bennett+M%2C+Roeckl-Wiedmann+I%2C+Debus+S&rft.date=2004&rft.issue=2&rft.pages=CD004123&rft_id=info:doi/10.1002%2F14651858.CD004123.pub2&rft_id=info:pmid/15106239&rfr_id=info:sid/en.wikipedia.org:Diabetic_foot">  </li>
<li id="cite_note-Veves-38">^ Veves A et.al, Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial, Diabetes Care(2001). 24: 2001–295 PMID 11213881. </li>
<li id="cite_note-Falanga-39">^ Falanga V et.al, A bilayered living skin construct (Apligraf) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen(1999). 7:201-207 PMID 10781211. </li>
<li id="cite_note-Mostow-40">^ Mostow EN, et.al. Effectiveness of an Extracellular Matrix Graft (OASIS Wound Matrix) in the Treatment of Chronic Leg Ulcers: A Randomized Clinical Trial. J Vas Surg(2005). 41:856-862 PMID 15886669. </li>
<li id="cite_note-Brigido-41">^ Stephen A. Brigido et.al,Use of an Acellular Flowable Dermal Replacement Scaffold on Lower Extremity Sinus Tract Wounds,Foot & Ankle Specialist(2009),2(2):67-72 </li>
<li id="cite_note-Voigt-42">^ David W. Voigt et.al, Economic Study of Collagen-Glycosaminoglycan Biodegradable Matrix for Chronic Wounds, Wounds(2006). 18(1):1-7 [3] </li>
<li id="cite_note-Armstrong-43">^ Armstrong DG et al, Outcomes of subatmospheric pressure dressing therapy on wounds of the diabetic foot. Ostomy Wound Manage(2002). 48(4): 64–68 PMID 11993062. </li>
<li id="cite_note-Tsang-44">^ Tsang MWet.al, Human Epidermal Growth Factor Enhances Healing of Diabetic Foot Ulcers. Diabetes Care(2003).26 (6):1856 PMID 12766123. </li>
</ol>
</div>
<h2>See also</h2>
<ul>
<li>Diabetic diet </li>
<li>Diabetic foot ulcer healing </li>
</ul>
<h2>External links</h2>
<ul>
<li><a class="external text" href="http://diabetic-foot.net" rel="nofollow">Diabetic Foot Research Page</a> at the Southern Arizona Limb Salvage Alliance (SALSA); for Professionals and Patients </li>
<li><a class="external text" href="http://gentili.net/diabeticfoot/" rel="nofollow">Imaging of the Diabetic Foot and Its Complications</a> </li>
<li><a class="external text" href="http://diabeticfootonline.blogspot.com/" rel="nofollow">The Diabetic Foot Blog</a> </li>
<li><a class="external text" href="http://www.podiatrytoday.com/article/5164" rel="nofollow">Assessing The Potential of Nitric Oxide in the Diabetic Foot</a> </li>
</ul>

<div class="printfooter"></div>

18.224.73.124

0

edits

Opengenome.net β

Changes

Diabetic foot ulcer

Opengenome.net ^β